| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H23FN2O2 |
| Molecular Weight | 366.4286 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(C=C1)C(=O)CN2CCC(CN3CC4=C(C=CC=C4)C3=O)CC2
InChI
InChIKey=RNRYULFRLCBRQS-UHFFFAOYSA-N
InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2
| Molecular Formula | C22H23FN2O2 |
| Molecular Weight | 366.4286 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CYR-101 (MIN-101) is a cyclic amide derivative that has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively). MIN-101 also shows binding affinity for a1-adrenergic receptors but low or no affinity for muscarinic, cholinergic, and
histaminergic receptors. MIN-101 demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients. The drug is in phase II clinical trials for the treatment of Schizophrenia.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Sample Use Guides
After at least 5 days' withdrawal from all antipsychotic medication, Schizophrenia patients were randomly assigned to receive 32 mg/day or 64 mg/day of oral CYR-101 (MIN-101) for 12 weeks.
Route of Administration:
Oral
